The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Ono, Kyowa Kirin, BMS to Conduct PI Study of Opdivo and Poteligeo as Combination Therapy in Patients with Solid Tumors
December 11, 2014
- Humanized Bispecific Antibody for Hemophilia A Effective in PI Study: Chugai
December 10, 2014
- Alfresa to Acquire More Shares of Pharmacy Chain Operator
December 10, 2014
- Ethical Drug Sales 1.1%, in October: Crecon Report
December 10, 2014
- Efficacy of Lenalidomide in Treatment-Naïve Patients with Multiple Myeloma Confirmed in Domestic PII Study: Celgene
December 10, 2014
- Takeda, Monash University of Australia to Collaborate in Gastroenterology Field
December 10, 2014
- Data Suggest Potential Feasibility of Ixazomib as Maintenance Therapy for Multiple Myeloma: Takeda
December 9, 2014
- Eisai’s Fycompa Cuts Tonic-Clonic Seizure Frequency by 76.5%
December 9, 2014
- Adcetris Significantly Extends PFS in Post-Transplant Hodgkin lymphoma Patients: Takeda
December 9, 2014
- Abilify Maintena Approved for Use in Acutely Relapsed Adults with Schizophrenia in the US: Otsuka, Lundbeck
December 9, 2014
- April-September Sales Drop 21.5% for Major Long-Listed Products
December 8, 2014
- Daiichi Sankyo to Harness Ties with Cardiologists in Lixiana Promotion
December 8, 2014
- Pfizer Japan Launches CML Drug Bosulif
December 8, 2014
- Zenyaku Kogyo to Initiate Preclinical Study for Nucleic Acid Medicine for Psoriasis as Early as Next Year
December 8, 2014
- COPD Drug Ultibro Launched in UK
December 8, 2014
- CareNet, EP-PharmaLine to Jointly Provide Online, Phone Detailing Services
December 8, 2014
- Nipro Sets Up New Sales Firm in Malaysia
December 8, 2014
- Nippon Chemiphar to Set Up Plant in Vietnam, Operation Launch Slated in 2018
December 5, 2014
- First-Line Xalkori Shows Superiority to Chemotherapy in ALK-Positive NSCLC: Pfizer
December 5, 2014
- Chiome Bioscience Succeeds in Producing Antibody to Ebola
December 5, 2014
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…